Bioline RX (BLRX) said Friday that results from a pilot phase 2 clinical trial of its drug motixafortide, along with cemiplimab and standard-of-care chemotherapies, as a first-line treatment for pancreatic cancer showed that four out of 11 patients remained progression-free after more than one year.
The study is evaluating the motixafortide combination against gemcitabine and nab-paclitaxel alone, the company said.
An analysis also revealed that tumor infiltration increased in all eleven patients treated with the motixafortide combination, the company said.
In all, the trial showed an overall response rate of 64% and a disease control rate of 91%, compared to historical rates of 23% and 48%, respectively, for gemcitabine and nab-paclitaxel, the company said.
The company said the trial will now increase enrollment in a randomized study to 108, from the previous 30, by 2027.
Shares of the company were up more than 64% in recent premarket activity.
Price: 6.25, Change: +2.46, Percent Change: +64.87
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.